Furthermore, an amylin analogue, Pramlintide, infused in migraine patients led to a migraine episode in a percentage of patients similar to that in whom CGRP was infused, suggesting a role of the amylin receptors in migraine pathogenesis [27]. This evidence concerns the gene CALCA and migraine disorder.